Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Non-Steroidal Anti-inflammatory Drugs Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The non-steroidal anti-inflammatory drugs market has experienced robust growth in recent years. It is projected to expand from $21.89 billion in 2025 to $23.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. This historical expansion can be attributed to the rising prevalence of arthritis and musculoskeletal disorders, increasing awareness of pain management therapies, an expanding geriatric population, the growth of retail pharmacies, and advancements in drug formulation technologies.
The non-steroidal anti-inflammatory drugs market is expected to demonstrate robust expansion in the coming years, with projections indicating it will reach $29.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.5%. This anticipated growth throughout the forecast period is fueled by elements such as the increasing adoption of personalized medicine, the development of e-pharmacy platforms, intensified research and development into innovative NSAID formulations, a rising prevalence of chronic inflammatory diseases, and the integration of digital health solutions for pain monitoring. Key trends for this period include personalized pain management strategies, a growing consumer demand for over-the-counter anti-inflammatory drugs, the creation of rapid-acting formulations, a concentrated effort on managing chronic pain and arthritis, and the expansion of online pharmacy distribution channels.
Get A Free Sample Report With In-Depth Market Insights:
Non-Steroidal Anti-inflammatory Drugs Market Growth Factors Behind Sustained Expansion
The rising occurrence of musculoskeletal conditions is anticipated to fuel the expansion of the non-steroidal anti-inflammatory drug market in the future. Musculoskeletal disorders (MSDs) encompass a wide range of ailments impacting the musculoskeletal system, such as muscles, bones, tendons, ligaments, joints, and other connective tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) are vital for addressing pain and inflammation linked to conditions like arthritis, osteoarthritis, and rheumatoid arthritis. Several elements contribute to this rise, including an aging demographic, enhanced understanding and identification of musculoskeletal disorders, orthopedic surgeries, athletic injuries, and the persistent character of these ailments. For example, GOV.UK, a UK-based government department, reported in January 2024 that in 2023, 18.4% of individuals aged 16 and older had a long-term musculoskeletal (MSK) condition, an increase from the 17.6% prevalence observed in 2022. Consequently, the growing prevalence of musculoskeletal disorders is stimulating the expansion of the non-steroidal anti-inflammatory drugs market. The increasing occurrence of chronic pain is anticipated to propel the expansion of the non-steroidal anti-inflammatory drugs (NSAIDs) market and associated pain management solutions in the future. Chronic pain is defined as ongoing or recurring pain that persists for three months or more, often stemming from ailments like arthritis, fibromyalgia, back pain, neuropathic pain, and other musculoskeletal disorders. Such conditions considerably diminish patients’ quality of life and frequently necessitate sustained management, involving medication, physical therapy, and supplementary care. The rising incidence of chronic pain escalates the need for potent pain relief treatments, including NSAIDs and various analgesic preparations. For example, the National Center for Biotechnology Information, a US-based federal government research and information organization, stated in October 2024 that 24.3% of adults reported enduring chronic pain, with 8.5% reporting high-impact chronic pain that restricts daily activities. Thus, the increasing population experiencing chronic pain is projected to boost the demand for pain management therapies, thereby fostering the growth of the NSAIDs market and its associated products.
Non-Steroidal Anti-inflammatory Drugs Market Segment Breakdown: Which Categories Lead On Revenue?
The non-steroidal anti-inflammatory drugs market covered in this report is segmented –
1) By Route Of Administration: Oral, Topical, Other Route Of Administration
2) By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Oral: Tablets, Capsules, Liquids Or Solutions
2) By Topical: Gels, Creams, Patches
3) By Other Route Of Administration: Injectable (Intravenous And Intramuscular), Suppositories
Non-Steroidal Anti-inflammatory Drugs Market Industry Trends Fueling Future Revenue Growth
Companies within the non-steroidal anti-inflammatory drugs (NSAIDs) market are concentrating on creating innovative remedies, such as combination analgesic–gastroprotective formulations, to satisfy the increasing demand for effective pain relief with diminished gastrointestinal risks commonly associated with prolonged NSAID usage. These combined technologies integrate an NSAID with a protective agent to uphold anti-inflammatory efficacy while preventing stomach irritation, offering a safer alternative to conventional single-agent NSAIDs. For instance, in March 2024, Endo International plc, an Ireland-based pharmaceutical company, introduced ibuprofen-famotidine 800 mg/26.6 mg tablets, an advanced product that merges the analgesic and anti-inflammatory properties of ibuprofen with the gastroprotective action of famotidine. This dual-action tablet is engineered to alleviate pain while minimizing gastrointestinal side effects, such as ulcers or irritation, which frequently occur with extended NSAID therapy, thereby enhancing safety and improving patient adherence.
Non-Steroidal Anti-inflammatory Drugs Market Leading Players And Competitive Positioning
Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Perrigo Company PLC, Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company
View The Full Non-Steroidal Anti-inflammatory Drugs Market Report:
Non-Steroidal Anti-inflammatory Drugs Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
